findmyKOL
Clinical trialNCT01954992RecruitingPhase 3Interventional

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

SponsorEleison Pharmaceuticals LLC.Enrollment480Metastatic Pancreatic Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Innovative Clinical Research Institute

    Whittier, California, United States

    Richy Agajanian, MD
    Recruiting
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Richard Kim, MD
    Recruiting
  • Gabrail Cancer Center Research

    Canton, Ohio, United States

    Nashat Gabrail, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2014
Primary completion
30 Jun 2026
Completion
31 Dec 2026
Last update posted
31 Dec 2024
Registered enrollment
480
Registry id
NCT01954992
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.